Muscle Wasting Disorders Market Report 2026

Muscle Wasting Disorders Market Overview

• Muscle Wasting Disorders market size has reached to $17.49 billion in 2025 • Expected to grow to $33.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.8% • Growth Driver: Sedentary Lifestyle Trends Fueling Growth In The Muscle Wasting Disorders Market • Market Trend: Innovative Advancements In The Muscle Wasting Disorders Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Muscle Wasting Disorders Market?

Muscle wasting disorders, or muscle atrophy or muscle wasting, refer to a condition characterized by a diverse group of conditions that cause the progressive loss of muscle mass and strength. This can occur as a result of various factors, including disuse, aging, malnutrition, neurodegenerative diseases, and certain medical conditions. The main treatments of muscle wasting disorders are medications, physical therapy, nutritional therapy, surgery, gene therapy, and others. Muscle wasting disorder medications refer to drugs that are used to treat conditions such as sarcopenia, cachexia, and muscular dystrophy. These medications aim to increase muscle mass and improve muscle function. They are used for the treatment of muscular dystrophy, amyotrophic lateral sclerosis (ALS), and others by hospitals, rehab centers, specialty clinics, and other end-users.

What Is The Muscle Wasting Disorders Market Growth Forecast?

The muscle wasting disorders market size is expected to see rapid growth in the next few years. It will grow to $33.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to advancements in gene therapy technologies, growing investment in regenerative medicine, expansion of specialized rehab centers, increasing demand for personalized treatment plans, rising focus on nutritional interventions. Major trends in the forecast period include rising adoption of gene therapy for muscle regeneration, growing use of nutritional and protein supplementation, increased demand for physical rehabilitation programs, expansion of targeted therapies for muscular dystrophy, rising utilization of hormonal and anti-inflammatory medications.

Global Muscle Wasting Disorders Market Segmentation

1) By Treatment Type: Medications, Physical Therapy, Nutritional Therapy, Surgery, Gene Therapy, Other Treatment Types 2) By Disorder Type: Muscular Dystrophy, Amyotrophic Lateral Sclerosis (ALS), Other Disorder Types 3) By End-User: Hospitals, Rehab Centers, Specialty Clinics, Other End-Users Subsegments: 1) By Medications: Anabolic Steroids, Hormonal Treatments, Anti-Inflammatory Drugs, Immunomodulatory Agents 2) By Physical Therapy: Resistance Training, Stretching Exercises, Aerobic Conditioning, Rehabilitation Programs 3) By Nutritional Therapy: Protein Supplements, Nutritional Counseling, Dietary Modifications, Micronutrient Supplements 4) By Surgery: Surgical Interventions For Muscle Repair, Orthopedic Surgeries, Procedures For Underlying Conditions 5) By Gene Therapy: Gene Replacement Therapy, CRISPR-Based Approaches, RNA Interference Techniques 6) By Other Treatment Types: Complementary Therapies, Psychological Support, Assistive Devices

What Is The Driver Of The Muscle Wasting Disorders Market?

Rising adherence to a sedentary lifestyle is expected to propel the growth of the muscle wasting disorders market going forward. A sedentary lifestyle refers to a lifestyle in which an individual is physically inactive and engages in little or no physical movement or exercise. Sedentary behavior can negatively impact muscle function, leading to a decline in muscle strength and endurance, contributing to muscle wasting disorders, and making it more difficult for individuals to maintain their muscle mass and function. For instance, in March 2025, according to the NHS England, a UK-based executive non-departmental public body, more than one-quarter of adults were classified as inactive, while almost one-third of children and young people (30.2 percent) in 2023 engaged in less than 30 minutes of daily physical activity. Therefore, rising adherence to a sedentary lifestyle is driving the growth of the muscle wasting disorders industry.

Key Players In The Global Muscle Wasting Disorders Market

Major companies operating in the muscle wasting disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Cytokinetics Incorporated, Scholar Rock, Akashi Therapeutics, aTyr Pharma, MyoTherix Inc., Pephexia Therapeutics, Biophytis SA, TNF Pharmaceuticals Inc., Rejuvenate Biomed, Edgewise Therapeutics

Global Muscle Wasting Disorders Market Trends and Insights

Major companies operating in the muscle wasting disorders market are developing innovative products, such as novel gene therapy, to better serve patients with muscle wasting disorders. Novel gene therapy refers to a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or altering the biological properties of living cells. For instance, in June 2023, Sarepta Therapeutics, a US-based biotechnology company, introduced Elevidys, which is the first gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in pediatric patients between the ages of 4 and 5 years old. Elevidys is a recombinant gene therapy designed to deliver into the body a gene that leads to a shortened protein that contains selected domains of the dystrophin protein of normal muscle cells. The product is administered as a single intravenous infusion.

What Are Latest Mergers And Acquisitions In The Muscle Wasting Disorders Market?

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals Inc. for $7.3 billion. With the acquisition, Biogen is expected to bolster Biogen's rare disease portfolio with the addition of Friedreich's ataxia, which is a genetic, progressive, life-shortening, debilitating, and degenerative disease that affects the nervous system and muscles. Reata Pharmaceuticals Inc. is a US-based pharmaceutical company focused on developing therapeutics for neuromuscular disorders and muscle wasting disorders.

Regional Outlook

North America was the largest region in the muscle wasting disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Muscle Wasting Disorders Market?

The muscle wasting disorders market consists of revenues earned by entities by providing services such as diagnostic services, medical services, support services and community services. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle wasting disorders market also includes sales of anabolic steroids, growth hormone, enobosarm and bimagrumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Muscle Wasting Disorders Market Report 2026?

The muscle wasting disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the muscle wasting disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.